Sharon W Y Law1, Wallis C Y Lau2, Ian C K Wong2, Gregory Y H Lip3, Michael T Mok4, Chung-Wah Siu5, Esther W Chan6. 1. Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. 2. Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; Research Department of Practice and Policy, UCL School of Pharmacy, London, United Kingdom. 3. Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. 4. Department of Cardiology, University Hospital Geelong, Geelong, Victoria, Australia; School of Medicine, Deakin University, Geelong, Victoria, Australia. 5. Cardiology Division, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China. 6. Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. Electronic address: ewchan@hku.hk.
Abstract
BACKGROUND: Women with atrial fibrillation are at a higher risk of stroke, despite treatment with warfarin. It is unclear if women treated with direct oral anticoagulants (DOACs) have better clinical outcomes, especially when considering the quality of anticoagulation control of warfarin. OBJECTIVES: This study compared the effectiveness and safety outcomes of DOACs versus warfarin in men and women with stratifications for anticoagulation control. METHODS: Patients newly diagnosed with atrial fibrillation and prescribed oral anticoagulants during 2010 to 2015 were identified using the Hong Kong clinical database. Propensity score matching was performed in men and women separately. Further analysis was conducted to stratify warfarin users according to their anticoagulation control. Cox regression was used to compare the risk of ischemic stroke or systemic embolism, intracranial hemorrhage (ICH), gastrointestinal bleeding, and all-cause mortality in the specific sex. RESULTS: There were 4,972 men and 4,834 women successfully matched in our cohort. Compared with warfarin, DOAC use was associated with a lower risk of ICH (hazard ratio [HR]: 0.16; 95% confidence interval [CI]: 0.06 to 0.40) and all-cause mortality (HR: 0.55; 95% CI: 0.39 to 0.77) in women but not in men. The treatment by sex interaction was significant for ICH only, and a significantly lower risk of ICH remained in the DOAC group when compared with warfarin users with good anticoagulation control (HR: 0.13; 95% CI: 0.02 to 1.00) among women only. The risks of ischemic stroke or systemic embolism and gastrointestinal bleeding with DOACs versus warfarin were comparable in both sexes. CONCLUSIONS: DOACs were associated with a lower risk of ICH and all-cause mortality in women only, where the association of lower ICH risk remained when compared with warfarin users with good anticoagulation control.
BACKGROUND:Women with atrial fibrillation are at a higher risk of stroke, despite treatment with warfarin. It is unclear if women treated with direct oral anticoagulants (DOACs) have better clinical outcomes, especially when considering the quality of anticoagulation control of warfarin. OBJECTIVES: This study compared the effectiveness and safety outcomes of DOACs versus warfarin in men and women with stratifications for anticoagulation control. METHODS:Patients newly diagnosed with atrial fibrillation and prescribed oral anticoagulants during 2010 to 2015 were identified using the Hong Kong clinical database. Propensity score matching was performed in men and women separately. Further analysis was conducted to stratify warfarin users according to their anticoagulation control. Cox regression was used to compare the risk of ischemic stroke or systemic embolism, intracranial hemorrhage (ICH), gastrointestinal bleeding, and all-cause mortality in the specific sex. RESULTS: There were 4,972 men and 4,834 women successfully matched in our cohort. Compared with warfarin, DOAC use was associated with a lower risk of ICH (hazard ratio [HR]: 0.16; 95% confidence interval [CI]: 0.06 to 0.40) and all-cause mortality (HR: 0.55; 95% CI: 0.39 to 0.77) in women but not in men. The treatment by sex interaction was significant for ICH only, and a significantly lower risk of ICH remained in the DOAC group when compared with warfarin users with good anticoagulation control (HR: 0.13; 95% CI: 0.02 to 1.00) among women only. The risks of ischemic stroke or systemic embolism and gastrointestinal bleeding with DOACs versus warfarin were comparable in both sexes. CONCLUSIONS:DOACs were associated with a lower risk of ICH and all-cause mortality in women only, where the association of lower ICH risk remained when compared with warfarin users with good anticoagulation control.
Authors: Raisa L Silva; Emily N Guhl; Andrew D Althouse; Brandon Herbert; Michael Sharbaugh; Utibe R Essien; Leslie R M Hausmann; Jared W Magnani Journal: Am J Prev Cardiol Date: 2021-09-03
Authors: Carlos K H Wong; Kenneth K C Man; Margaret Shi; Esther W Chan; Chu Wa Ho; Emily T Y Tse; Ian C K Wong; Cindy L K Lam Journal: PLoS Med Date: 2019-12-26 Impact factor: 11.069
Authors: Sharen Lee; Jiandong Zhou; Wing Tak Wong; Tong Liu; William K K Wu; Ian Chi Kei Wong; Qingpeng Zhang; Gary Tse Journal: BMC Endocr Disord Date: 2021-05-04 Impact factor: 2.763
Authors: Ching-Lung Cheung; Chor-Wing Sing; Wallis C Y Lau; Gloria H Y Li; Gregory Y H Lip; Kathryn C B Tan; Bernard M Y Cheung; Esther W Y Chan; Ian C K Wong Journal: Cardiovasc Diabetol Date: 2021-03-25 Impact factor: 9.951
Authors: Vinita Subramanya; J'Neka S Claxton; Pamela L Lutsey; Richard F MacLehose; Lin Y Chen; Alanna M Chamberlain; Faye L Norby; Alvaro Alonso Journal: BMC Cardiovasc Disord Date: 2021-12-16 Impact factor: 2.298
Authors: Alexander C Perino; Jun Fan; Krishna Pundi; Susan Schmitt; Mitra Kothari; Natasha Din; Paul A Heidenreich; Mintu P Turakhia Journal: Clin Cardiol Date: 2022-08-09 Impact factor: 3.287
Authors: David S Eccleston; Joseph M Kim; Jurien M Ten Berg; P Gabriel Steg; Deepak L Bhatt; Stefan H Hohnloser; Anne de Veer; Matias Nordaby; Corinna Miede; Takeshi Kimura; Gregory Y H Lip; Jonas Oldgren; Christopher P Cannon Journal: Clin Cardiol Date: 2021-05-27 Impact factor: 2.882